At Aurigene, we have over 20 years of experience in crystallization, polymorph screening and development, salt screening and powder X-ray diffraction.
We also offer services for studying physical properties like particle size reduction, bulk density, powder flow etc.
Polymorph Screening
- Polymorph studies are performed with the API material
- Solvent screening is performed with following solvents - ICH-3: Ethyl acetate, n- Butyl acetate, IPA, MTBE, MIBK, Acetone, Heptane, n-Butanol, IPAC and 2- Methyl THF, DMSO etc.
ICH-2: Acetonitrile, Dichloromethane, Hexane, Methanol, Tetrahydrofuran, Toluene, 1, 4-Dioxane, Di –Isopropyl ether, cyclohexane etc. - Detailed solvent screening at different temperatures to classify the solvents as anti or co-solvents
- Solubility curve generation, identification of Metastable Zone Width (MSZW)
- Solubility studies are performed with ~95% pure material
Crystallization and Polymorphism
Crystallization experiments are performed to understand the process conditions to get the different morphs. Those are either solvated, non-solvated, hydrated or hemihydrated. Various crystallization techniques are used for screening the solid forms:
- Cooling crystallization
- Anti-solvent crystallization
- Seeding crystallization (Seed point evaluation)
- Evaporative crystallization
- Spray drying
- Agitated thin film dryer
Polymorph-slurry Mediated Transformations
Various forms of the test compounds are subjected to slurry-mediated transformation studies in organic solvents which are having optimum solubility -
- Slurring media, volume and solid content are appropriately adjusted to make sure that excess solid is present.
- Time points of the slurry experiments can be decided as per requirements. Solid forms that remained after slurring either in organic solvents or aqueous phase mixtures are separated and subjected to solid-form characterization (PXRD, DSC, and TGA).
Polymorph or Crystallization Process Optimization
- Crystallization process are optimized with PAT like FBRM (Focused Beam Reflectance Measurement) which shows online particle counts and chord length distributions of the particles and PVM (Particle Vision Microscope) which shows online particle shape
- Process finalization to achieve desired yield and quality parameters
- ATFD studies if required, in case of amorphous forms and heat-sensitive materials
Optimization of Filtration, Drying and Particle Size Distribution
- Filtration and drying studies from a scale-up point of view to optimize the conditions
- Particle size distribution & milling studies are performed based on the requirement
- Stress studies for solids (polymorph stability with milling and micronation)
- Well equipped lab and plant infrastructure with multi-mills, centrifuges, micronizer and ANFDs
We also have a tangential flow filter which is used for separation of compounds based on molecular weights.
Why Aurigene Pharmaceutical Services?
Expertise and experience of 20+ years
Comprehensive infrastructure at lab and plant for full suite of services
State-of-the-art PAT tools and QbD approach to support optimization
Phase-appropriate development approach
Other Services
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Polymorph Screening
Resources
JULY 02, 2021
Oligonucleotide as a novel class of therapeutic modality
Oligonucleotides as a therapeutic class is a revolutionary approach to discover new and important therapeutic agents for treating human diseases. RNA-based intervention at times works in cases where other modalities do not work. For example, it may help in treating inborn errors in metabolism, genetic disorders and rareOligonucleotide therapeutics is the use of c...
Read More
Evolution in Pharma Industry and Demand for Integrated CDMO
The pharma industry is evolving and a demand for integrated CDMOs, which can help accelerating innovations, is part of the evolution....
Read More
Systematic formulation design - shorten development cost & time
Project Challenge: Existing formulation (lower strength - 50 mg) was manufactured using direct compression process. This formulation posed poor powder flow and content uniformity issues during scale-up. Development of new strength 150 mg without any process issues was a challenge. Solution design: Preliminary pre-formulation, stress study and PSD impact assessmen...
Read More
A metal catalyst-free and one-pot synthesis of (3,4- dihydro-2H-benzo[b][1,4]oxazin-2-yl)methanol derivatives in water
2015
A robust and metal catalyst-free method has been developed for the general and green synthesis of racemic (3,4-dihydro-2H-benzo[b][1,4] oxazin-2-yl)methanol derivatives. This simple, mild and practical method involves the reaction of 2-aminophenols with ()-epichlorohydrin in the presence of NaOH in water at room temperature. The reaction features high regioselec...
Read More-
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2005
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More -
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2005
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.